次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

幹細胞技術のリーデイング企業2014-2024年

Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2014年3月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文171ページになります。
商品コード:VGN194

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
Visiongain社では幹細胞技術の世界市場は2018年に122億ドルに達し、2024年にかけて高い成長を見せると予測しています。当レポートでは、幹細胞技術のリーディング企業22社を特定し、その技術、業績、トレンド、市場機会、収益予測など2014年以降の展望、および同技術の世界市場予測を概略以下の構成でお届けしています。

【レポート構成概要】
・幹細胞技術のリーディング企業22社分析(米国、欧州、イスラエル、アジア)
・全194ページ、106個のデータ表、グラフ類で分析定量化
・技術、研究開発(R&D)パイプライン、製品、業績
・企業買収、提携、技術アプリケーション、臨床開発
・SWOT分析
・収益予測
・米国のリーディング企業(以下含め10社)
• Advanced Cell Technology (ACT)VGN194_Pharma Leader Series Top Stem Cell Technology Companies 2014-2024 Cover.jpgレポート表紙
• BrainStorm Cell Therapeutics
• Bioheart
• International Stem Cell Corporation (ISCO)
• NeoStem
• Osiris Therapeutics.

・欧州およびイスラエルのリーディング企業(以下含め7社)
• apceth
• Cardio3 BioSciences
• Cell Cure Neurosciences
• TiGenix
• Gamida Cell
• Pluristem Therapeutics.

・アジアのリーディング企業(5社)
• Anterogen
• MEDIPOST
• Mesoblast
• Pharmicell
• Stempeutics Research.

・幹細胞技術の世界市場予測2014-2024年
・セグメント別市場予測2014-2024年
• がん治療Cancer treatment (oncology)
• 心血管Cardiovascular (CV) applications
• 中枢神経系Central nervous system (CNS) uses
• その他治療法Other therapy using those biological agents
• 非治療用途細胞製品Non-therapeutic cellular products.

・技術とポテンシャル
• ヒト胚性幹細胞。組織修復および再生
• 自家移植、同種移植(T細胞治療含む)
• 遺伝子組換え癌治療
• 骨髄移植における細胞移植
• 臍帯血。組織や細胞バンキングのアプリケーション
• 非治療、製薬向けアプリケーション

【レポート詳細目次は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Top Stem Cell Technology Companies 2014-2024

Table of Contents

1. Executive Summary

1.1 Top Stem Cell Technology Companies: Overview of Findings
1.2 Report Contents
1.3 Study Methods - Research and Analysis
1.4 Scope and Format of Report

2. Leading US Stem Cell Technology Companies, 2014

2.1 Aastrom Biosciences
2.1.1 Stem Cell Technology Platform
2.1.2 Aastrom: Stem Cell Pipeline, 2014
2.1.2.1 Ixmyelocel-T: Patient-Specific Therapy Reduces Risk of Rejection
2.1.2.2 Orphan Designation to Accelerate Product Development
2.1.3 Sales and Recent Performance, 2012
2.1.4 Aastrom: Stem Cell SWOT Analysis, 2014-2024
2.1.5 Aastrom: Stem Cell Revenue Forecast, 2014-2024
2.2 Advanced Cell Technology (ACT)
2.2.1 Stem Cell Technology Platform
2.2.2 ACT: Stem Cell R&D Pipeline, 2014
2.2.2.1 Human Embryonic Stem Cells: Aiding Tissue Repair
2.2.3 Sales and Recent Performance, 2012
2.2.4 ACT: Stem Cell SWOT Analysis, 2014-2024
2.2.5 ACT: Stem Cell Revenue Forecast, 2014-2024
2.3 Bioheart
2.3.1 Bioheart: Stem Cell Pipeline, 2014
2.3.2 Sales and Recent Performance, 2012
2.3.3 Bioheart: Stem Cell SWOT Analysis, 2014-2024
2.3.4 Bioheart: Stem Cell Revenue Forecast, 2014-2024
2.3.4.1 Increased Activity Abroad Will Help Bioheart Attract Investment
2.4 BrainStorm Cell Therapeutics
2.4.1 Brainstorm Cell Therapeutics: Stem Cell Pipeline, 2014
2.4.2 Brainstorm Cell Therapeutics: Stem Cell SWOT Analysis, 2014-2024
2.4.3 Brainstorm Cell Therapeutics: Stem Cell Revenue Forecast, 2014-2024
2.4.3.1 Government Grant Will Provide Much Needed Investment
2.5 California Stem Cell Inc.
2.5.1 California Stem Cell: Stem Cell Pipeline, 2014
2.5.2 California Stem Cell: Stem Cells SWOT Analysis, 2014-2024
2.6 International Stem Cell Corporation (ISCO)
2.6.1 ISCO: Stem Cell Pipeline, 2014
2.6.2 Sales and Recent Performance, 2012
2.6.3 ISCO: Stem Cells SWOT Analysis, 2014-2024
2.6.4 Cosmetic Subsidiary Expands Into Asian Market
2.7 NeoStem
2.7.1 NeoStem: Stem Cell Pipeline, 2014
2.7.1.1 AMR-001: Highly Efficacious Therapy for AMI
2.7.1.2 T-Cell Therapy: Using Autologous Immune Cells as Therapy
2.7.1.3 VSEL Technology: Promoting Cell Migration to Site of Damage
2.7.2 Sales and Recent Performance, 2012
2.7.3 NeoStem: Stem Cell SWOT Analysis, 2014-2024
2.7.4 NeoStem: Stem Cell Revenue Forecast, 2014-2024
2.8 Neuralstem
2.8.1 Stem Cell Technology Platform
2.8.2 Neuralstem: Stem Cell Pipeline, 2014
2.8.2.1 NSI-566: Potential Therapy in Multiple Neurological Disorders
2.8.2.2 NSI-189: Deriving Cells from the Hippocampal Region
2.8.3 Sales and Recent Performance, 2012
2.8.4 Neuralstem: Stem Cell SWOT Analysis, 2014-2024
2.8.5 Neuralstem: Stem Cell Revenue Forecast, 2014-2024
2.9 Medistem
2.9.1 Medistem: Stem Cell Pipeline, 2014
2.9.2 Medistem: Stem Cell SWOT Analysis, 2014-2024
2.9.3 Medistem: Stem Cell Revenue Forecast, 2014-2024
2.9.3.1 Expansion of Clinical Indications Through Acquisition
2.10 Osiris Therapeutics
2.10.1 Osiris Therapeutics: Stem Cell Products
2.10.2 Osiris Therapeutics: Stem Cell Pipeline, 2014
2.10.3 Sales and Recent Performance, 2012
2.10.4 Osiris Therapeutics: Stem Cell SWOT Analysis, 2014-2024
2.10.5 Osiris Therapeutics: Stem Cell Revenue Forecast, 2014-2024
2.11 Other US Companies Operating in the Stem Cells Technology Industry, 2014

3. Top European and Israeli Stem Cell Technology Companies, 2014

3.1 Apceth
3.1.1 Apceth: Stem Cell Pipeline, 2014
3.1.1.1 Alecmestencel-T: Options for Autologous and Allogeneic Therapy
3.1.1.2 Agenmestencel-T: Genetically-modified Therapy for Cancer
3.1.2 Apceth: Stem Cell SWOT Analysis, 2014-2024
3.1.3 Apceth: Stem Cell Revenue Forecast, 2014-2024
3.2 Cardio3 BioSciences
3.2.1 Cardio3 BioSciences: Stem Cell Pipeline, 2014
3.2.1.1 C-Cure®: Creating New Muscle Cells
3.2.2 Cardio3 BioSciences: Stem Cell SWOT Analysis, 2014-2024
3.2.3 Cardio3 BioSciences: Stem Cell Revenue Forecast, 2014-2024
3.3 Cell Cure Neurosciences
3.3.1 Cell Cure Neurosciences: Stem Cell Pipeline, 2014
3.3.2 Cell Cure Neurosciences: Stem Cell SWOT Analysis, 2014-2024
3.4 TiGenix
3.4.1 Stem Cell Technology Platform
3.4.2 TiGenix: Stem Cell Products
3.4.2.1 ChondroCelect: One of Few Marketed Stem Cell Products
3.4.3 TiGenix: Stem Cell Pipeline, 2014
3.4.3.1 Cx601: Promoting Natural Close of Fissure
3.4.3.2 Cx611: Landmark Results of a Cell Therapy in Rheumatoid Arthritis
3.4.3.3 Cx621: Novel, Painless Route of Administration?
3.4.4 Sales and Recent Performance, 2012
3.4.5 TiGenix: Stem Cell SWOT Analysis, 2014-2024
3.4.6 TiGenix: Stem Cell Revenue Forecast, 2014-2024
3.5 Gamida Cell
3.5.1 Stem Cell Technology Platform
3.5.1.1 Copper Chelator-based Technology
3.5.1.2 Nicotinamide (NAM) Platform
3.5.2 Gamida Cell: Stem Cell Pipeline, 2014
3.5.2.1 StemEx: Huge Market Potential in Patient Numbers
3.5.2.2 NiCord: Transplanting Two Units of Umbilical Cord Blood
3.5.3 Gamida Cell: Stem Cell SWOT Analysis, 2014-2024
3.5.4 Gamida Cell: Stem Cell Revenue Forecast, 2014-2024
3.6 Pluristem Therapeutics
3.6.1 Stem Cell Technology Platform:
3.6.2 Pluristem Therapeutics: Stem Cell Pipeline, 2014
3.6.2.1 PLX-PAD: Clinical Hold Notification May Delay Approval
3.6.2.2 PLX-RAD: Accelerating Cell Engraftment in Bone Marrow Transplantation
3.6.3 US and Korea Licence Partnerships to Drive Revenue
3.6.4 Sales and Recent Performance, 2013
3.6.5 Pluristem Therapeutics: Stem Cell SWOT Analysis, 2014-2024
3.6.6 Pluristem Therapeutics: Stem Cell Revenue Forecast, 2014-2024
3.7 ReNeuron
3.7.1 ReNeuron: Stem Cell Technology Platform
3.7.2 ReNeuron: Stem Cell Pipeline, 2014
3.7.2.1 ReN001: Groundbreaking Therapy in Development
3.7.2.2 ReN009: Avoiding Possible Limb Amputation
3.7.2.3 ReN003: Grant and Partnership with Leading US University Will Drive Development
3.7.3 Sales and Recent Performance, 2013
3.7.4 ReNeuron: Stem Cell SWOT Analysis, 2014-2024
3.7.5 ReNeuron: Stem Cell Revenue Forecast, 2014-2024
3.8 Other European and Israeli Companies Operating in the Stem Cells Technology Industry, 2014

4. Top Asia-Pacific Stem Cell Technology Companies, 2014

4.1 Anterogen
4.1.1 Anterogen: Stem Cell Products
4.1.1.1 Cupistem®: World's First MSC Product From Adipose Tissue
4.1.1.2 Queencell®:
4.1.2 Anterogen: Stem Cell Pipeline, 2014
4.1.3 Anterogen: Stem Cell SWOT Analysis, 2014-2024
4.2 MEDIPOST
4.2.1 Stem Cell Technology Platform
4.2.2 MEDIPOST: Stem Cell Pipeline, 2014
4.2.2.1 Cartistem: A Top 25 Science Technology
4.2.2.2 Neurostem: Restorative Therapy for Neurological Disease
4.2.2.3 Pneumostem: Treatment for Paediatric Population
4.2.2.4 Promostem: Encouraging Engraftment of Cells Following Transplantation
4.2.3 Sales and Recent Performance, 2014
4.2.4 MEDIPOST: Stem Cell SWOT Analysis, 2014-2024
4.2.5 MEDIPOST: Stem Cell Revenue Forecast, 2014-2024
4.2.5.1 Collaboration with an Indian Company Expands Reach in Asia
4.3 Mesoblast
4.3.1 Stem Cell Technology Platform
4.3.2 Mesoblast: Stem Cell Pipeline, 2014
4.3.2.1 Immunology and Inflammatory Diseases
4.3.2.2 Spinal Disease
4.3.2.3 Cardiac and Vascular Disease
4.3.2.4 Oncology
4.3.2.5 Other Indications
4.3.3 Sales and Recent Performance, 2012
4.3.4 Mesoblast: Stem Cell SWOT Analysis, 2014-2024
4.3.5 Mesoblast: Stem Cell Revenue Forecast, 2014-2024
4.4 Pharmicell
4.4.1 Pharmicell: Stem Cell Products
4.4.1.1 Hearticellgram-AMI: World First Cell Therapy for Acute Myocardial Infarction
4.4.2 Pharmicell: Stem Cell Pipeline, 2014
4.4.3 Sales and Recent Performance, 2012
4.4.4 Pharmicell: Stem Cell SWOT Analysis, 2014-2024
4.4.5 Pharmicell: Stem Cell Revenue Forecast, 2014-2024
4.5 Stempeutics Research
4.5.1 Stem Cell Technology Platform
4.5.2 Stempeutics Research: Stem Cell Pipeline, 2014
4.5.2.1 Stempeucel®: Launch in Fast-Growing Asian Markets
4.5.2.2 Stempeucare™: Cosmetic Growth Factor Treatment
4.5.3 Stempeutics Research: Stem Cell SWOT Analysis, 2014-2024
4.5.4 Stempeutics Research: Stem Cell Revenue Forecast, 2014-2024
4.5.4.1 Cipla Alliance to Drive Revenue as Wider Population Targeted

5. The World Stem Cell Technology Market, 2014-2024

5.1 The World Stem Cell Technology Market, 2012
5.2 The World Stem Cell Technology Market: Revenue Forecast to 2024
5.2.1 What Will Drive The World Stem Cell Technology Market Between 2014 and 2024?
5.2.2 What Factors are Likely to Restrain the World Stem Cell Technology Market Between 2014 and 2024?
5.3 The Stem Cell Technology Market: Revenue Forecast by Therapeutic Application, 2014-2024
5.3.1 How Will Market Shares of Leading Stem Cell Therapeutic Applications Change from 2014-2024?

6. Stem Cell Technologies: Industry Trends, 2014-2024

6.1 Strengths and Weaknesses of The Stem Cell Technologies Market
6.2 Strengths
6.2.1 Stem Cells Are Finally Proving Their Worth
6.3 Weaknesses
6.3.1 Many Difficulties Still to Overcome
6.4 Opportunities and Threats in the Stem Cell Technologies Market
6.4.1 Stem Cells Have Unprecedented Clinical Potential
6.4.2 Regulatory and Commercial Instability Threatens the Field
6.5 STEP Analysis of the Stem Cell Technologies Market, 2014-2024
6.5.1 Social Concerns: A Controversial Technology
6.5.2 Technological Developments: Stem Cell Science Still on the March
6.5.3 Economic Factors: Funding Gaps a Concern
6.5.4 Political Issues: State Attitudes Vital to Research Environment

7. Opinions from Research Interviews

7.1 Dr Robin Smith: Chairman and CEO, NeoStem
7.1.1 The Potential of Stem Cell Therapy
7.1.2 Competition in the Stem Cell Arena
7.1.3 NeoStem's Products and Technology
7.1.4 Concerns over Stem Cell Therapy
7.1.5 Future Directions for NeoStem and Stem Cell Therapy
7.2 Dr Yael Margolin, President and CEO, Gamida Cell
7.2.1 Stem Cell Therapy and Their Therapeutic Promise
7.2.2 Gamida Cell's NiCord Product and Umbilical Cord Blood
7.2.3 Partnership with a Leading Pharmaceutical Company
7.2.4 Barriers to Stem Cell Therapy Uptake

8. Conclusions

8.1 The US Leads the Field for Stem Cell Research
8.2 Market Remains Under-Capitalised, in Need of Financing
8.3 Many Barriers Still to Overcome for Companies
8.4 New Entrants to the Market Will Increase Competition

List of Tables

Table 2.1 Aastrom Biosciences: Key Facts, 2014
Table 2.2 Aastrom: Stem Cell Development Pipeline, 2014
Table 2.3 Aastrom: Revenues ($), 2008-2012
Table 2.4 Aastrom: Stem Cell SWOT Analysis, 2014-2024
Table 2.5 Aastrom: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.6 Advanced Cell Technology: Key Facts, 2014
Table 2.7 ACT: Stem Cell Development Pipeline, 2014
Table 2.8 ACT: Revenues ($m), 2008-2012
Table 2.9 ACT: Stem Cell SWOT Analysis, 2014-2024
Table 2.10 ACT: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.11 Bioheart: Key Facts, 2014
Table 2.12 Bioheart: Stem Cell Development Pipeline, 2014
Table 2.13 Bioheart: Revenues ($m, CAGR %), 2011-2012
Table 2.14 Bioheart: Stem Cell SWOT Analysis, 2014-2024
Table 2.15 Bioheart: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.16 BrainStorm Cell Therapeutics: Key Facts, 2014
Table 2.17 BrainStorm Cell Therapeutics: Stem Cell Development Pipeline, 2014
Table 2.18 BrainStorm Cell Therapeutics: Stem Cell SWOT Analysis, 2014-2024
Table 2.19 BrainStorm Cell Therapeutics: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.20 California Stem Cells: Key Facts, 2014
Table 2.21 California Stem Cell: Stem Cell Development Pipeline, 2014
Table 2.22 California Stem Cell: Stem Cell SWOT Analysis, 2014-2024
Table 2.23 ISCO: Key Facts, 2014
Table 2.24 ISCO: Stem Cell Development Pipeline, 2014
Table 2.25 ISCO: Revenues ($m, CAGR %), 2011-2012
Table 2.26 ISCO: Stem Cell SWOT Analysis, 2014-2024
Table 2.27 NeoStem: Key Facts, 2014
Table 2.28 NeoStem: Stem Cell Development Pipeline, 2014
Table 2.29 NeoStem: Revenues ($m, CAGR %) by Sector, 2011-2012
Table 2.30 NeoStem: Stem Cell SWOT Analysis, 2014-2024
Table 2.31 NeoStem: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.32 Neuralstem: Key Facts, 2014
Table 2.33 Neuralstem: Stem Cell Development Pipeline, 2014
Table 2.34 Neuralstem: Revenues ($m), 2011-2012
Table 2.35 Neuralstem: Stem Cell SWOT Analysis, 2014-2024
Table 2.36 Neuralstem: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.37 Medistem: Key Facts, 2014
Table 2.38 Medistem: Stem Cell Development Pipeline, 2014
Table 2.39 Medistem: Stem Cell SWOT Analysis, 2014-2024
Table 2.40 Medistem: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.41 Osiris Therapeutics: Key Facts, 2014
Table 2.42 Osiris Therapeutics: Stem Cell Development Pipeline, 2014
Table 2.43 Osiris Therapeutics: Revenues ($m) by Sector, 2008-2012
Table 2.44 Osiris Therapeutics: Stem Cell SWOT Analysis, 2014-2024
Table 2.45 Osiris Therapeutics: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.46 Other US Companies Operating in the Stem Cells Technology Industry, 2014
Table 3.1 Apceth: Key Facts, 2014
Table 3.2 Apceth: Stem Cell Development Pipeline, 2014
Table 3.3 Apceth: Stem Cell SWOT Analysis, 2014-2024
Table 3.4 Apceth: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.5 Cardio3 BioSciences: Key Facts, 2014
Table 3.6 Cardio3 BioSciences: Stem Cell Development Pipeline, 2014
Table 3.7 Cardio3 BioSciences: Stem Cell SWOT Analysis, 2014-2024
Table 3.8 Cardio3 BioSciences: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.9 Cell Cure Neurosciences: Key Facts, 2014
Table 3.10 Cell Cure Neurosciences: Stem Cell Development Pipeline, 2014
Table 3.11 Cell Cure Neurosciences: Stem Cell SWOT Analysis, 2014-2024
Table 3.12 TiGenix: Key Facts, 2014
Table 3.13 TiGenix: Stem Cell Development Pipeline, 2014
Table 3.14 TiGenix: ChondroCelect Revenues ($m, CAGR %), 2010-2012
Table 3.15 TiGenix: ChondroCelect Revenues ($m) and Market Share (%) by Region, 2012
Table 3.16 TiGenix: Stem Cell SWOT Analysis, 2014-2024
Table 3.17 TiGenix: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.18 Gamida Cell: Key Facts, 2014
Table 3.19 Gamida Cell: Stem Cell Development Pipeline, 2014
Table 3.20 Gamida Cell: Stem Cell SWOT Analysis, 2014-2024
Table 3.21 Gamida Cell: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.22 Pluristem Therapeutics: Key Facts, 2014
Table 3.23 Pluristem Therapeutics: Stem Cell Development Pipeline, 2014
Table 3.24 Pluristem Therapeutics: Revenue ($m, CAGR %), 2012-2013
Table 3.25 Pluristem Therapeutics: Stem Cell SWOT Analysis, 2014-2024
Table 3.26 Pluristem Therapeutics: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.27 ReNeuron: Key Facts, 2014
Table 3.28 ReNeuron: Stem Cell Development Pipeline, 2014
Table 3.29 ReNeuron: Revenue ($m, CAGR %), 2012-2013
Table 3.30 ReNeuron: Stem Cell SWOT Analysis, 2014-2024
Table 3.31 ReNeuron: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.32 Other European and Israeli Companies Operating in the Stem Cells Technology Industry, 2014
Table 4.1 Anterogen: Key Facts, 2014
Table 4.2 Anterogen: Stem Cell Development Pipeline, 2014
Table 4.3 Anterogen: Stem Cell SWOT Analysis, 2014-2024
Table 4.4 MEDIPOST: Key Facts, 2014
Table 4.5 MEDIPOST: Stem Cell Development Pipeline, 2014
Table 4.6 MEDIPOST: Revenue ($m, CAGR %), 2009-2012
Table 4.7 MEDIPOST: Stem Cell SWOT Analysis, 2014-2024
Table 4.8 MEDIPOST: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.9 Mesoblast: Key Facts, 2014
Table 4.10 Mesoblast: Stem Cell Development Pipeline, 2014
Table 4.11 Mesoblast: Revenues ($m) and Change (%), By Sector, 2012-2013
Table 4.12 Mesoblast: Stem Cell SWOT Analysis, 2014-2024
Table 4.13 Mesoblast: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.14 Pharmicell: Key Facts, 2014
Table 4.15 Pharmicell: Stem Cell Development Pipeline, 2014
Table 4.16 Pharmicell: Revenues ($m), 2011-2012
Table 4.17 Pharmicell: Stem Cell SWOT Analysis, 2014-2024
Table 4.18 Pharmicell: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.19 Stempeutics Research: Key Facts, 2014
Table 4.20 Stempeutics Research: Stem Cell Development Pipeline, 2014
Table 4.21 Stempeutics Research: Stem Cell SWOT Analysis, 2014-2024
Table 4.22 Stempeutics: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 5.1 The World Stem Cell Technology Market: Revenue ($m) and Market Share (%) by Therapeutic Application, 2012
Table 5.2 The World Stem Cell Technology Market: Revenue Forecasts ($m, AGR %, CAGR %) by Therapeutic Application, 2013-2024
Table 5.3 The World Stem Cell Technology Market: Market Shares (%) by Therapeutic Application, 2012-2024
Table 6.1 The World Stem Cell Technologies Market: Strengths and Weaknesses, 2014
Table 6.2 The World Stem Cell Technologies Market: Opportunities and Threats, 2014-2024
Table 6.3 The World Stem Cell Technologies Market: STEP Analysis, 2014-2024

List of Figures

Figure 2.1 Aastrom: Revenues ($), 2008-2012
Figure 2.2 Aastrom: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 2.3 ACT: Revenues ($m), 2008-2012
Figure 2.4 ACT: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 2.5 Bioheart: Revenues ($m), 2011-2012
Figure 2.6 Bioheart: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 2.7 BrainStorm Cell Therapeutics: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 2.8 ISCO: Revenues ($m) 2011-2012
Figure 2.9 NeoStem: Revenues ($m) by Sector, 2011-2012
Figure 2.10 NeoStem: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 2.11 Neuralstem: Revenues ($m), 2011-2012
Figure 2.12 Neuralstem: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 2.13 Medistem: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Figure 2.14 Osiris Therapeutics: Revenues ($m) by Sector, 2008-2012
Figure 2.15 Osiris Therapeutics: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 3.1 Apceth: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 3.2 Cardio3 BioSciences: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 3.3 TiGenix: ChondroCelect Revenues ($m), 2010-2012
Figure 3.4 TiGenix: Market Share (%) by Region, 2012
Figure 3.5 TiGenix: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 3.6 Gamida Cell: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 3.7 Pluristem Therapeutics: Revenue ($m, CAGR %), 2012-2013
Figure 3.8 Pluristem Therapeutics: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 3.9 ReNeuron: Revenue ($m), 2012-2013
Figure 3.10 ReNeuron: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 4.1 MEDIPOST: Revenue ($m), 2009-2012
Figure 4.2 MEDIPOST: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 4.3 Mesoblast: Revenues ($m), by Sector, 2012-2013
Figure 4.4 Mesoblast: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 4.5 Pharmicell: Revenues ($m), 2011-2012
Figure 4.6 Pharmicell: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 4.7 Stempeutics: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 5.1 The World Stem Cell Technology Market: Market Share (%) by Therapeutic Application, 2012
Figure 5.2 The World Stem Cell Technology Market: Overall Revenue Forecast ($m), 2013-2024
Figure 5.3 The World Stem Cell Technology Market: Drivers and Restraints, 2014-2024
Figure 5.4 The World Stem Cell Technology Market: Revenue Forecasts ($m) by Therapeutic Application, 2013-2024
Figure 5.5 The World Stem Cell Technology Market: Market Shares (%) by Therapeutic Application, 2018
Figure 5.6 The World Stem Cell Technology Market: Market Share (%) by Therapeutic Application, 2024

掲載企業リスト

Companies Listed

Aastrom Biosciences
Advanced Cell Technology (ACT)
African-Middle East Medical (AFRIMID)
Alkem Laboratories
AlloCure
Alphatec Spine
Amorcyte
Anosis
Anterogen
Antria
Apceth
Athelos Corporation
Athersys
Axiogenesis
Becton-Dickinson
BioCardia
BioE
Biogenea Pharmaceuticals
Bioheart
Biomet Orthopedics
BioTime
Bluebird Bio
BrainStorm Cell Therapeutics
California Stem Cell Inc.
Capricor Therapeutics
Cardio3 BioSciences
Cell Cure Neurosciences
Cell Line Genetics
Cellectis
Cellerant Therapeutics
Celltex Therapeutics
Cellular Dynamics International
CHA Bio & Diostech
Cipla
Cognate BioServices
Cook General BioTechnology
Cryo-Cell International
Cryo-Save
Cytomedix
Cytori Therapeutics
DaVinci Biosciences
Dendreon
Dong-A Pharmaceutical
Drug Controller General of India
Epistem
ERCell LLC
European Medicines Agency (EMA)
Fibrocell Science
Food and Drug Administration (FDA)
Forticell Bioscience
Gamida Cell
Garnet BioTherapeutics
Genzyme
Geron
GlobalStem
Hadassah University Hospital
Harvard Medical School
Health Canada
Human Stem Cells Institute
Immunocellular Therapeutics
Intellicell BioSciences
Intercytex
International Stem Cell Corporation (ISCO)
Intrexon Corporation
Invitrx Therapeutics
InVivo Therapeutics
iPierian
Jules Stein Eye Institute
King's College London
Lentigen
Lifeline Skin Care
Lincoln Park Capital Fund
Lonza
MEDIPOST
Medistem
Merck & Co.
Merck Millipore
Mesoblast
National Academy of Engineering (Korea)
NeoStem
Neuralstem
NeuroGeneration
Novartis
NuVasive
Office of the Chief Scientist (Israel)
OncoCyte
OncoMed Pharma
Orgenesis
OrthoCyte
Osiris Therapeutics
OvaScience
Pharmicell
Plasticell Therapeutics
Pluristem Therapeutics
Progenitor Cell Therapy
Proneuron Biotechnologies
Ramot
ReCyte Therapeutics
Regen BioPharma
Regenerative Sciences
RegenoCELL Therapeutics
ReNeuron
RhinoCyte
Roslin Cellab
Rush University Medical Center
SanBio
Saneron CCEL Therapeutics
Sanofi
Schepens Eye Research Institute
South Korea Food and Drug Administration (SFDA)
Stem Cell Medicine
Stem Cell Sciences
StemCells
Stemcyte
Stemedica Cell Technologies
Stemline Therapeutics
Stempeutics Research
Stratatech Corporation
Targazyme (formerly America Stem Cell, Inc.)
TCA Cellular Therapy
Technology Strategy Board (UK)
Tel Aviv University
Teva Pharmaceuticals
The Isar Medical Centre
TiGenix
Tissue Genesis
United Therapeutics
US Department of Defence
US National Academy of Sciences
Vesta Therapeutics
ViaCyte
VistaGen
Vital Therapies
Vitro Biopharma
Wizbang Technologies
World Health Organization (WHO)

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

関連レポート紹介

幹細胞技術と製品の世界市場2015-2025年

臨床段階の企業が、筋萎縮性側索硬化症(ALS)およびパーキンソン病のような中枢神経系(CNS)疾患に注力しているほか、加齢性黄斑変性症(AMD)などの眼症状にも取り組んでいます。関連治療法、治療機器、システムの将来性は強力であり、多くの市場機会が存在しているといえるでしょう。

レポートページへLinkIcon

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。